Expert Opinion on Biological Therapy

Influenza as a bioterror threat: the need for global vaccination
pp. 265-267(3)
Authors: Madjid M.; Casscells W.

Cell therapies for type 1 diabetes mellitus
pp. 269-277(9)
Authors: Shamblott M.J.; Clark G.O.

Cytokine therapy for craniosynostosis
pp. 279-299(21)
Authors: Mooney M.P.; Moursi A.M.; Opperman L.A.; Siegel M.I.

Protein crystals for the delivery of biopharmaceuticals
pp. 301-317(17)
Authors: Basu S.K.; Govardhan C.P.; Jung C.W.; Margolin A.L.

Therapeutic potential of retroviral RNAi vectors
pp. 319-327(9)
Authors: Devroe E.; Silver P.A.

Ebola virus glycoproteins: guidance devices for targeting gene therapy vectors
pp. 329-336(8)
Author: Sanders D.A.

Recent advances in the development of peptide nucleic acid as a gene-targeted drug
pp. 337-348(12)
Authors: Marin V.L.; Roy S.; Armitage B.A.

Novel peptide-based HIV-1 immunotherapy
pp. 349-361(13)
Authors: Sommerfelt M.A.; Nyhus J.; Sørensen B.

Cancer immunotherapy and heat-shock proteins: promises and challenges
pp. 363-373(11)
Authors: Manjili M.H.; Wang X-Y.; MacDonald I.J.; Arnouk H.; Yang G.Y.; Pritchard M.T.; Subjeck J.R.

Monoclonal antibody therapy of B cell lymphoma
pp. 375-385(11)
Authors: Weiner G.J.; Link B.K.

Pathogen-specific recombinant human polyclonal antibodies: biodefence applications
pp. 387-396(10)
Authors: Bregenholt S.; Haurum J.

Exploiting immune surveillance mechanisms in mucosal vaccine development
pp. 397-406(10)
Author: Lo D.

Apoptosis as a tool for therapeutic agents in haematological diseases
pp. 407-420(14)
Authors: Alenzi F.Q.; Wyse R.K.; Altamimi W.G.

Pegvisomant: a novel pharmacotherapy for the treatment of acromegaly
pp. 421-425(5)
Authors: Paisley A.N.; Trainer P.; Drake W.

Expediting target identification and validation through RNAi
pp. 427-429(3)
Author: Kurreck J.